1979
Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse.
Fisher R, DeVita V, Hubbard S, Simon R, Young R. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Annals Of Internal Medicine 1979, 90: 761-3. PMID: 434676, DOI: 10.7326/0003-4819-90-5-761.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseProlonged disease-free survivalDisease-free survivalLong-term survivalMOPP chemotherapyMOPP therapyComplete remissionMedian survivalMedian durationRe-treatmentMOPPRemissionHodgkinPatientsRelapseReinductionNitrogen mustardMonthsSurvivalDiseasePrednisoneDurationProcarbazineChemotherapyVincristine
1976
Effect of Splenectomy on Tolerance to Combination Chemotherapy in Patients With Lymphoma
Ihde D, DeVita V, Canellos G, Young R. Effect of Splenectomy on Tolerance to Combination Chemotherapy in Patients With Lymphoma. Blood 1976, 47: 211-222. DOI: 10.1182/blood.v47.2.211.211.Peer-Reviewed Original ResearchTolerance to combination chemotherapyCombination chemotherapyHodgkin's diseasePlatelet countControl patientsBone marrow lymphomaSplenectomy per seCycles of therapyCycles of treatmentMatched control patientsPortion of patientsEffect of splenectomyHodgkin lymphomaLymphoma patientsInitial treatmentStaging procedureLymphomaTotal doseSplenectomyChemotherapyLeukocyte countHodgkinPatientsLeukocytesPlateletEffect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma.
Ihde D, DeVita V, Canellos G, Young R. Effect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma. Blood 1976, 47: 211-22. PMID: 1244920, DOI: 10.1182/blood.v47.2.211.bloodjournal472211.Peer-Reviewed Original ResearchConceptsTolerance to combination chemotherapyCombination chemotherapyHodgkin's diseasePlatelet countControl patientsBone marrow lymphomaSplenectomy per seCycles of therapyNon-Hodgkin's lymphomaCycles of treatmentMatched control patientsPortion of patientsEffect of splenectomyLymphoma patientsInitial treatmentStaging procedureLymphomaTotal doseSplenectomyChemotherapyLeukocyte countPatientsHodgkinLeukocytesPlatelet
1975
In vitro granulocyte production in patients with Hodgkin's disease and lymphocytic, histiocytic, and mixed lymphomas.
Bull J, DeVita V, Carbone P. In vitro granulocyte production in patients with Hodgkin's disease and lymphocytic, histiocytic, and mixed lymphomas. Blood 1975, 45: 833-42. PMID: 1125431, DOI: 10.1182/blood.v45.6.833.bloodjournal456833.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseMixed lymphomaUntreated patientsHistiocytic-lymphocytic lymphomasAdvanced Hodgkin's diseaseMOPP chemotherapyGranulocyte colony formationCombination chemotherapyMarrow culturesCFU-CIn vitro examinationLymphomaChemotherapyGranulocyte productionPatientsLong-term effectsAcute responseHodgkinColony formationDecreased numberDiseaseColony growthIn Vitro Granulocyte Production in Patients With Hodgkin’s Disease and Lymphocytic, Histiocytic, and Mixed Lymphomas
Bull J, DeVita V, Carbone P. In Vitro Granulocyte Production in Patients With Hodgkin’s Disease and Lymphocytic, Histiocytic, and Mixed Lymphomas. Blood 1975, 45: 833-842. DOI: 10.1182/blood.v45.6.833.833.Peer-Reviewed Original ResearchHodgkin's diseaseMixed lymphomaUntreated patientsHistiocytic-lymphocytic lymphomasAdvanced Hodgkin's diseaseMOPP chemotherapyGranulocyte colony formationCombination chemotherapyMarrow culturesCFU-CIn vitro examinationLymphomaChemotherapyGranulocyte productionPatientsLong-term effectsAcute responseHodgkinColony formationDecreased numberDiseaseColony growth
1972
Hodgkin's Disease Therapeutic Program
DeVita V. Hodgkin's Disease Therapeutic Program. JAMA 1972, 222: 1171-1171. PMID: 4678060, DOI: 10.1001/jama.1972.03210090051025.Peer-Reviewed Original ResearchConceptsCombination of drugsRemission durationHodgkin's diseaseCombinations of effective drugsProlongation of remission durationAdvanced Hodgkin's diseaseComplete remission rateAcute childhood leukemiaRemission rateProcarbazine hydrochlorideRate of inductionCooperative trialsEffective drugsChildhood leukemiaRemissionTherapyDrugPilot studyDiseaseHodgkinDurationMOPPProcarbazineMethotrexateLeukemia